Andy Lundin

The CDMO has expanded production at its Bioconjugation Center of Excellence in St. Louis and partnered with Simtra to better serve the growing antibody-drug conjugate market.

Cytiva's 2025 Global Biopharma Index shows widening gaps across regions as talent shortages, regulatory strain, and uneven sustainability progress weigh on growth.

John Murphy III, president and CEO of the Association for Accessible Medicines, unpacks what's working, what's not, and what must change for U.S. generic drug production.

Terumo Blood and Cell Technologies and The Blood Center in New Orleans look to transform the platelet processing landscape.

Following major investments in peptide and API capacities, CEO Thomas Loewald discusses supply chain localization, biotech funding trends, and scaling to meet demand.

By pairing AMTs with underutilized U.S. facilities, APIIC aims to expand domestic manufacturing of critical medicines and strengthen pharmaceutical supply chain.

The company is growing its RLT production network in the U.S. as part of a planned $23 billion investment in infrastructure over five years.

New data from USP reveals that 48 of the 100 vulnerable U.S. medicines are dependent on a key starting material sourced from at least one country.

As regulatory support grows for botanical therapies, developers face the complex task of standardizing nature for pharmaceutical production.

Workforce growth, logistics infrastructure, and education investments are solidifying the area's position as an up-and-coming cluster in North Carolina.